10 News & Press Releases found
XELTIS BV News
-
Xeltis accelerating clinical trial program
Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the ...
-
Vascular experts discuss aXess in dialysis patients
Vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The ...
-
Xeltis receives €15M funding from EIC Accelerator
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support ...
-
First restorative hemodialysis access graft implanted in patients
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part ...
-
Xeltis opens new horizons in hemodialysis at VERVE
To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his ...
-
Xeltis lands €15 million European financing from EIB
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, ...
-
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients ...
-
Dutch Secretary of State visits Xeltis following RegMedXB funding
The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners. Minister Mona Keijzer met executives from the RegMedXB ...
-
CEO Eliane Schutte among Top 50 Medtech CEOs
Xeltis CEO Eliane Schutte has been included in the Healthcare Technology Report’s list of 2021 Top 50 Healthcare Technology CEOs, one of only seven women featuring on the list. The Report’s list recognizes the most ...
-
Xeltis CTO at FDA-led Pediatric Device Innovators Forum
Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. Food and Drug Administration (FDA) in conjunction with five U.S. pediatric device ...